Pablo Cerezuela-Fuentes

7PUBLICATIONS
47CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)NanomedicineMedical mycologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 15, 2026
Correction: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.

|Jul 07, 2026
Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

|Dec 20, 2025
Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801.

Pablo Cerezuela-Fuentes, Antonio Piñero-Madrona, Eva Muñoz-Couselo

|Jun 27, 2025
BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag

|Feb 26, 2025
An MGRN1-Based Biomarker Combination Accurately Predicts Melanoma Patient Survival.

José Sánchez-Beltrán, Javier Soler Díaz, Cecilia Herraiz

|Dec 14, 2024
Characterization of thrombosis risk in ambulatory patients with cancer: results of the observational, prospective, multicenter CARTAGO study.

Javier Trujillo-Santos, Ignacio García-Escobar, Mercedes Salgado

Pageof 2

Frequent Collaborators

2 joint publications

Iván Márquez-Rodas

1 joint publications

Javier Trujillo-Santos

1 joint publications

Ignacio García-Escobar

1 joint publications

Mercedes Salgado